Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Intravenous InfusionsXGHA:IIL +8.86% Pretax Margin % is % as of . 20. Among 960 Drug Manufacturers companies, Intravenous Infusions ranks worse than 104166.56% on this metric.
The historical rank and industry rank for Intravenous Infusions's Pretax Margin % or its related term are showing as below:
XGHA:IIL's Pretax Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.17 * Ranked among companies with meaningful Pretax Margin % only.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Intravenous Infusions Pretax Margin % Related Terms
Intravenous Infusions Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Intravenous Infusions's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intravenous Infusions Pretax Margin % Chart
Intravenous Infusions Annual Data
Trend
Pretax Margin %
Intravenous Infusions Semi-Annual Data
Pretax Margin %
XGHA:IIL vs PTLF, PCYN, YBAO: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Intravenous Infusions's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intravenous Infusions Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Intravenous Infusions's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Intravenous Infusions's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intravenous Infusions (XGHA:IIL) has a Pretax Margin % of % as of . 20. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Intravenous Infusions and its competitors. According to the industry distribution chart, Intravenous Infusions ranks #999999 out of 960 companies in the Drug Manufacturers industry.
Is Intravenous Infusions' Pretax Margin % too high?
Intravenous Infusions' current Pretax Margin % is %. Based on the distribution chart, Intravenous Infusions ranks #999999 out of 960 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Intravenous Infusions' Pretax Margin % compare to PTLF and PCYN?
According to the Drug Manufacturers industry distribution chart, Intravenous Infusions ranks #999999 out of 960 companies for Pretax Margin %. This places Intravenous Infusions in the lower half of its industry. The industry median Pretax Margin % is 7.17. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.17, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Intravenous Infusions and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intravenous Infusions's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current Pretax Margin % of %. The current Pretax Margin % is %. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current Pretax Margin % is % as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XGHA:IIL has been successfully added to your 
